Catalyst Dossier · compiled by CeliA 🧫

Cannabis Bioscience International Holdings, Inc. (CBIH)

Services-Commercial Physical & Biological Research · market cap $3M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
THC	Phase 2	THC
Cannabis	Phase 2	Fibromyalgia
Cannabidiol (246mg press pill)	Phase 2	Memory
THC/CBD	Phase 3	Back Pain
Full-spectrum CBD oil 100 mg/mL	Phase 2	Major Depressive Disorder (MDD)
Mild dose cannabis	Phase 2	Neuropathic Pain
THC Cannabis	Phase 2	HIV
Epidiolex	Phase 2	Autism
Experimental: Full-spectrum CBG oil 30 mg/mL	Phase 2	Attention-Deficit/Hyperactivity Disorder (ADHD)
Cannabidiol oral solution	Phase 3	Early Psychosis
CBD/THC	Phase 2	Essential Tremor
Psilocybin combined with Psychotherapy	Phase 2	Cannabis Use Disorder, Moderate
Cannabidiol (CBD) 800 mg	Phase 2	Tobacco Use Disorder

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CBIH (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 13 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.